statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This is a signal that YMAB's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...

Y-mAbs Therapeutics (YMAB, $16.19) Stochastic Oscillator left the overbought zone on April 01, 2024

Public Employees Retirement System of Ohio trimmed its stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB  Free Report) by 11.0% during the third quarter, according to its most recent disclosure...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Position Cut by Public Employees Retirement System of Ohio

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB  Get Free Report) shot up 3.9% on Tuesday . The stock traded as high as $16.33 and last traded at $16.33. 4,518 shares traded hands during...

Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 3.9%

This indicator may be signaling YMAB's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

Y-mAbs Therapeutics (YMAB, $16.5) entered Uptrend as Momentum indicator ascends above 0 level on Mar 27, 2024

Shares of Y-mAbs Therapeutics, Inc. (YMAB) have gained 1% over the past four weeks to close the last trading session at $16.50, but there could still be a solid upside left in the stock if short-term...

Wall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Bet

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB  Get Free Report) have been assigned an average recommendation of Hold from the seven research firms that are presently covering...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $16.57 Average Price Target from Analysts

This price move could be a signal that YMAB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options...

Y-mAbs Therapeutics (YMAB, $13.76) price may climb as it broke lower Bollinger Band on Mar 18, 2024

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Y-mAbs Therapeutics CFO Bo Kruse resigns

NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs ) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...

Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer

Trexquant Investment LP boosted its stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB  Free Report) by 417.5% in the third quarter, according to the company in its most recent filing with the...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Holdings Raised by Trexquant Investment LP

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.

Watchers	650
52-Wk Low	$4.60
52-Wk High	$20.90

Volume	206,394.00
52-Wk High	$20.90
52-Wk Low	$4.60

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.14	--	--	N/A
Q4'23	-$0.20	-$0.02	90.07%	BEAT
Q3'23	-$0.19	-$0.18	4.15%	BEAT
Q2'23	-$0.24	-$0.14	42.14%	BEAT
Q1'23	-$0.32	-$0.15	53.01%	BEAT

YMAB Y-Mabs Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals